PubMed Health⌕ Search

Biomedical subjects

L Matthews

Publications and source records attributed to L Matthews.

57 records · Page 4Linked to original sources

Complete and sustained remission of refractory cervical cancer following a single cycle of capecitabine. A case report.

Cervical cancer with distant metastasis is almost always incurable. The treatment goal is to palliate the patient's symptoms with pain medications and localized radiation therapy. Chemotherapy generally has a limited role, with responses that are short lived. Newer agents investigated as potential therapy include fluorouracil prodrugs. We report on a case where capecitabine was used in metastatic cervical cancer with progression of disease outside the radiation field, following multiple drug regimens including one dose of cisplatin (discontinued due to transient renal toxicity), paclitaxel, and carboplatin and continuous infusion 5-fluorouracil (5-FU) The patient was treated with capecitabine 1100 mg/m2 twice daily for two weeks. After the first week of the cycle, the patient developed grade 2 toxicities consisting of mucositis and hand-foot Syndrome but she continued on therapy through day 14. On day 20 she was hospitalized with grade 4 toxicity, which included febrile neutropenia, urinary tract infection, pancytopenia, mucositis, hand-foot syndrome, and renal failure, all of which have subsequently completely resolved. Restaging demonstrated complete remission. Although the patient suffered toxicity related to capecitabine, 3.5 years post a single cycle of capecitabine, the patient remains in remission, with no evidence of disease reoccurence.

Administration, Oral↗

A case management approach to immunizing patients at high risk for influenza.

The influenza season affects not only the people afflicted with influenza, but the healthcare system as a whole. An estimated dollar 12 billion is the annual cost to care for these patients. An existing problem is that although there is an immunization for influenza, many patients at high risk are not immunized. This article will describe an innovative program of a large Midwest suburban hospital to immunize patients at high risk.

Case Management↗

Acarosan and the Acarex test in the control of house dust mite allergens in the home.

House dust mites are believed to be major triggers for allergic disease in atopic individuals. As part of a programme controlling dietary and aero-allergen exposure in high-risk infants, an acaricidal foam and powder (Acarosan) was applied to bedroom and main living room carpets, as well as upholstered furniture, on four occasions in the first year of life. Dust was assayed for mite antigen (Der p1) and these results compared with the semi-quantitative assay of guanine content (Acarex Test). After nine months mean Der p1 levels had decreased by 70% in the treatment group. Proportionally, the greatest fall occurred in those items that had the highest initial mite antigen content. The Acarex score does show a correlation with Der p1 levels, but cannot replace antigen assay when accurate data is required. A chemical acaricide may help reduce house dust mite antigen levels, but is not by itself sufficient to reduce levels below that considered critical for sensitisation.

Allergens↗